Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Prospective, Randomized, Multicenter, Active-controlled Study to Evaluate the Efficacy and Safety of BV100 Plus Low-dose Polymyxin B Compared With Colistin Plus High-dose Ampicillin/Sulbactam in the Treatment of Adult Patients With Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia Caused by Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex

Next Previous
Trial Profile

A Phase 3 Prospective, Randomized, Multicenter, Active-controlled Study to Evaluate the Efficacy and Safety of BV100 Plus Low-dose Polymyxin B Compared With Colistin Plus High-dose Ampicillin/Sulbactam in the Treatment of Adult Patients With Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia Caused by Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 23 Sep 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Polymixin B (Primary) ; Polymixin B (Primary) ; Rifabutin (Primary) ; Ampicillin/sulbactam; Colistin; Meropenem
  • Indications Acinetobacter infections; Nosocomial pneumonia; Ventilator associated pneumonia
  • Focus Registrational; Therapeutic Use
  • Acronyms BV100 RIV-TARGET; RIV-TARGET
  • Sponsors BioVersys

Most Recent Events

  • 09 Sep 2026 According to a BioVersys media release, The first Data Safety Monitoring Board (DSMB) review is anticipated by the end of 2026. Guidance remains for last patient enrolled for end of 2027, and first submissions for regulatory approval anticipated by mid-2028. Topline data read-out from RIV-TARGET is anticipated for early 2028.
  • 04 May 2026 Planned primary completion date changed from 1 Dec 2027 to 30 Dec 2027.
  • 16 Apr 2026 According to a BioVersys media release, the company announced the first patient first visit in this trial. This global pivotal Phase 3 trial is on track to enroll last patient by the end of 2027 and will support first regulatory approval submissions in 2028. The trial will enroll across ~100 sites in ~15 countries.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top